Capricor (CAPR) announced the European expansion of its partnership with Nippon Shinyaku (NPNKF), a U.S. subsidiary of NS Pharma, for exclusive commercialization and distribution of Duchenne Muscular Dystrophy treatment Deramiocel, Maxim analyst Jason McCarthy tells investors in a research note. While the deal is positive for Capricor and the expansion is further validating for Deramiocel, it may be more than that given the challenges the DMD space has faced in 2024 for exon-skipping medications on the market and gene therapy, Maxim says. The firm made no change to its Buy rating or $12 price target on Capricor shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics Secures Lucrative European Partnership
- Capricor Therapeutics enters deramiocel term sheet with Nippon Shinyaku
- Capricor signs term sheet with Nippon Shinyaku for deramiocel commercialization
- Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences